Katherine Stueland Sells 1,657 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 1,657 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total value of $130,041.36. Following the transaction, the chief executive officer now directly owns 3,937 shares in the company, valued at approximately $308,975.76. This trade represents a 29.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The stock was sold at an average price of $94.48, for a total value of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The shares were sold at an average price of $78.18, for a total value of $1,407,709.08.
• On Monday, December 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The shares were sold at an average price of $76.75, for a total value of $805,951.75.
• On Monday, December 9th, Katherine Stueland sold 3,661 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total value of $279,590.57.
• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The stock was sold at an average price of $70.34, for a total value of $1,569,074.38.
• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The shares were sold at an average price of $70.48, for a total value of $1,628,651.84.

GeneDx Stock Down 3.9 %

WGS traded down $3.01 on Friday, hitting $74.85. The company had a trading volume of 393,012 shares, compared to its average volume of 865,986. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. GeneDx Holdings Corp. has a 52-week low of $3.62 and a 52-week high of $98.87. The stock has a fifty day simple moving average of $78.37 and a 200-day simple moving average of $57.69. The firm has a market capitalization of $2.06 billion, a P/E ratio of -24.07 and a beta of 2.02.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.21) by $0.25. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The business had revenue of $76.90 million during the quarter, compared to analyst estimates of $64.98 million. During the same period last year, the business posted ($0.82) earnings per share. GeneDx’s quarterly revenue was up 44.3% compared to the same quarter last year. As a group, equities analysts expect that GeneDx Holdings Corp. will post -0.24 EPS for the current fiscal year.

Hedge Funds Weigh In On GeneDx

Several large investors have recently made changes to their positions in the business. MCF Advisors LLC lifted its holdings in shares of GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after purchasing an additional 182 shares during the last quarter. Global Retirement Partners LLC purchased a new position in shares of GeneDx during the fourth quarter valued at approximately $28,000. Rhumbline Advisers lifted its holdings in shares of GeneDx by 5.5% during the fourth quarter. Rhumbline Advisers now owns 19,750 shares of the company’s stock valued at $1,518,000 after purchasing an additional 1,021 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of GeneDx by 10.6% during the fourth quarter. Principal Financial Group Inc. now owns 15,751 shares of the company’s stock valued at $1,211,000 after purchasing an additional 1,511 shares during the last quarter. Finally, Palumbo Wealth Management LLC lifted its holdings in shares of GeneDx by 22.8% during the fourth quarter. Palumbo Wealth Management LLC now owns 8,303 shares of the company’s stock valued at $638,000 after purchasing an additional 1,542 shares during the last quarter. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on WGS. Craig Hallum raised their price objective on GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. The Goldman Sachs Group raised their target price on GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Wells Fargo & Company raised their target price on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 30th. Finally, TD Cowen raised their target price on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research note on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $70.67.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.